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Abstract We investigated the expression of peroxisome pro-
liferator-activated receptor Q (PPARQ) and the role of PPARQ in
cell growth in human gastric cancer cells. Reverse transcription-
polymerase chain reaction, Northern blot and Western blot
analyses showed that a human gastric cancer cell line, MKN45,
expressed PPARQ mRNA and protein. Luciferase assay in
MKN45 cells showed that troglitazone, a selective ligand for
PPARQ, transactivated the transcription of a peroxisome
proliferator response element-driven promoter. Troglitazone or
pioglitazone, selective ligands for PPARQ, inhibited the growth
of MKN45 cells in a dose-dependent manner. Co-incubation of
MKN45 cells with troglitazone induced DNA ladder formation.
These results suggest that human gastric cancer cells express
PPARQ and that activation of PPARQ inhibits cell growth and
induces apoptosis in gastric cancer cells.
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Key words: Peroxisome proliferator-activated receptor Q ;
Growth inhibition; Apoptosis; Gastric cancer
1. Introduction
Peroxisome proliferator-activated receptor Q (PPARQ), a nu-
clear hormone receptor, provides a strong link between lipid
metabolism and the regulation of gene transcription [1,2]. Re-
cent studies show that PPARQ is expressed at high levels in
human colonic mucosa and colon cancer cells [3^5]. Ligand
activation of PPARQ in human colon cancer cells causes a
reduction of growth [3,4]. In contrast, two independent
groups demonstrated that activation of PPARQ promoted
the development of colon tumors in mice [6,7]. Thus the roles
of PPARQ activation in the growth of colon tumors are con-
troversial. In addition to colon cancer, PPARQ activation in-
duced growth arrest in human liposarcoma, prostate cancer
and breast cancer [8^10]. These results suggest that PPARQ
activation may be implicated in the growth of malignant tu-
mors.
It has been reported that PPARQ gene expression is ob-
served in the heart, liver, small and large intestine, and kidney
in addition to the adipose tissue [5,11]. Braissant et al. have
shown, using in situ hybridization, that PPARQ is expressed in
the rat gastric mucosa [12]. Little is known, however, about
the pathophysiological relevance of PPARQ in the human gas-
tric mucosa. In the present study, we investigated the expres-
sion of PPARQ and examined the e¡ects of PPARQ activation
on cellular growth in human gastric cancer cells.
2. Materials and methods
2.1. Cell culture
The human gastric cancer cell line MKN45 was obtained from the
Japanese Cancer Research Resources Bank (Tsukuba, Japan).
MKN45 is a cell line established from a poorly di¡erentiated gastric
adenocarcinoma metastasized to liver [13]. MKN45 cells were cultured
in RPMI 1640 medium (Gibco, Grand Island, NY) supplemented
with 100 U/ml penicillin, 100 Wg/ml streptomycin, 2.5 Wg/ml ampho-
tericin, and 10% fetal bovine serum. Since the expression of PPARQ
protein has already been reported in a human colon cancer cell line,
HT-29 [3], we used this cell line as a positive control in experiments to
detect PPARQ mRNA and protein expression. HT-29 was purchased
from the American Type Culture Collection (Rockville, MD, USA)
and cultured in Dulbecco’s modi¢ed Eagle’s medium (Gibco, Grand
Island, NY) containing 450 mg/dl glucose and supplemented with
2 mM L-glutamine, MEM non-essential amino acid solution (Sigma-
Aldrich, Co., Irvine, UK), 100 U/ml penicillin, 100 Wg/ml streptomy-
cin, 2.5 Wg/ml amphotericin, and 10% fetal bovine serum. Cells were
incubated at 37‡C in a humidi¢ed atmosphere of 5% CO2 in air.
2.2. Chemicals
Troglitazone and pioglitazone were kindly provided from Sankyo
Pharmaceutical Co. (Tokyo, Japan) and Takeda Chemical Industries
(Osaka, Japan), respectively. These thiazolidinediones were dissolved
in dimethyl sulfoxide (DMSO) with a ¢nal concentration of 0.1%
DMSO in the culture medium.
2.3. RNA extraction
Total RNA was extracted from cultured cells using a modi¢ed
version of the acid guanidinium thiocyanate/phenol/chloroform meth-
od employing a single reagent (RNA-STAT 60, TelTest Inc., Friends-
wood, TX, USA) [14^16]. Samples were dissolved with diethyl pyro-
carbonate-treated water (RNase-free). To remove contaminating
genomic DNA, the RNA was treated with 10 Wl of RQ1, RNase-
free DNase (Promega, Madison, WI, USA), 0.5 Wl of RNase inhibitor
(Takara Shuzou Co., Otsu, Shiga, Japan) and 10 Wl of 10UDNase
bu¡er (400 mM Tris-HCl at pH 7.9, 100 mM NaCl, 60 mM MgCl2
and 100 mM CaCl2) in a ¢nal volume of 100 Wl for 30 min at 37‡C.
RNA samples were puri¢ed by phenol-chloroform extraction and iso-
propanol precipitation. The resultant RNA samples were quanti¢ed
using spectrophotometer at a wavelength of 260 nm. The integrity of
the isolated RNA samples was analyzed electrophoretically on an
agarose gel, followed by staining in ethidium bromide.
2.4. Reverse transcription PCR (RT-PCR)
An aliquot of 1 Wg of total RNA from each sample was reverse
transcribed to cDNA using a First-Strand cDNA Synthesis kit (Phar-
macia LKB Biotechnology, Uppsala, Sweden) according to the man-
ufacturer’s instructions with oligo(dT) primer. For detection of the
human PPARQ mRNA, a combination of a sense primer, 5P-
TCTCTCCGTAATGGAAGACC-3P, and an antisense primer, 5P-
GCATTATGAGACATCCCCAC-3P, was used as described previ-
ously [17]. For the detection of human L-actin mRNA, a combination
of a sense primer, 5P-AGGCCAACCGCGAGAAGATGACC-3P, and
an antisense primer, 5PGAAGTCCAGGGCGACGTAGCAC-3P, was
used according to a previous publication [18]. The ampli¢cation was
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carried out in a 100 Wl mixture containing 1 Wl of the above cDNA
product (corresponding to cDNA synthesized from 67 ng of total
RNA), 0.4 WM each of the sense and antisense primers, 10 mM
Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 200 WM dNTPs,
and 2.5 units of Taq DNA polymerase (Takara Shuzou Co., Otsu,
Shiga, Japan). The reaction conditions were as follows: initial dena-
turation at 95‡C for 2 min and 40 cycles of ampli¢cation (95‡C for 40
s, 55‡C for 50 s and 72‡C for 50 s), followed by a ¢nal extension step
of 7 min at 72‡C. The PCR reaction products were separated electro-
phoretically in a 2% agarose gel and stained with ethidium bromide.
2.5. Northern analysis
Total RNA (10 Wg) denatured in formamide and formaldehyde was
electrophoresed through 1% formaldehyde-containing agarose gels as
described previously [14]. After electrophoresis, the RNA was trans-
ferred to nylon membrane (Hybond N, Amersham International,
Buckinghamshire, UK) by the capillary blotting and then ¢xed by
UV cross-linker (FUNA-UV-LINKER, Funakoshi, Tokyo, Japan).
Prehybridization was performed at 42‡C for 2 h in 50% formamide,
25 mM sodium phosphate (pH 6.5), 0.1% sodium dodecyl sulfate
(SDS), 5USSC, 5U Denhardt’s solution and 100 Wg/ml denatured
salmon sperm DNA. Hybridization was carried out at the same tem-
perature for 20 h in the same solution with 32P-labeled cDNA probes.
Probe for PPARQ was ampli¢ed by PCR using MKN45 cell cDNA as
template and sequenced. A L-actin cDNA probe (Wako Chemicals
Industries, Osaka, Japan) was used as internal control. After washing
the membrane under appropriately stringent conditions, the hybrid-
ization signals were analyzed with a bioimaging analyzer system (Fuji-
BAS, Fuji Photo Film Co., Tokyo, Japan) or autoradiography using
XAR ¢lm (Eastman Kodak, Rochester, NY).
2.6. Western blot analysis
Total proteins were extracted from MKN45 and HT-29 cells. Pro-
tein concentrations were measured using Bio-Rad Protein Assay Re-
agent (Bio-Rad Lab., Richmond, CA, USA) following the manufac-
turer’s suggested procedure. 50 Wg of protein was separated by 10%
SDS-PAGE. After electrophoresis, the proteins were transferred to
nitrocellulose membrane (Amersham Life Science Inc., Piscataway,
NJ, USA), blocked overnight in TBS-Twin (TBS-T) with 10% skim
milk at 4‡C, subsequently reacted with primarily monoclonal antibody
against human PPARQ (Santa Cruz Lab., Santa Cruz, CA) and
washed. After reaction with horseradish peroxidase-conjugated anti-
mouse IgG, immune complexes were visualized by using the ECL
detection reagents (Amersham, Buckinghamshire, UK) following the
manufacturer’s suggested procedure. Simultaneously, mouse immuno-
globulin G1 kappa monoclonal immunoglobulin (Pharmingen, San
Diego, CA, USA) was used for isotype control.
2.7. Transfections and luciferase assays
Transfections and luciferase assays were performed according to a
previous report [19]. MKN45 cells were seeded at a concentration of
1U105 cells/35 mm dish and transfected with the plasmids 24 h after
having been transferred to fresh media. Transfection was done using
LipofectAMINE reagent (Gibco BRL) mixed with 2 Wg of acyl CoA
oxidase promoter-luciferase plasmid (kindly donated by Dr. Osumi)
[20] and 0.2 Wg of pRL-SV40 (Promega, Madison, WI, USA) for 3 h.
The transfection mix was replaced by complete medium with or with-
out 100 WM troglitazone and further incubated for 12 h. The cells
were lysed with 1Uluciferase lysis bu¡er (Toyo Ink, Tokyo, Japan).
Luciferase activity was measured using the PicaGene reagent kit
(Toyo Ink, Tokyo, Japan) in a luminometer (MiniLumat, Berthold,
Wildbad, Germany). The enzyme activity was normalized for e⁄-
ciency of transfection, on the basis of sea pansy luciferase activity,
and relative values were determined. Transfection experiments were
carried out two times independently, and the average values were
calculated.
2.8. Cell counting
First, we examined the dose-response e¡ects of thiazolidinediones
on the growth of MKN45 cells. MKN45 cells were seeded at a density
of 1U106 cells/25 cm2 cell culture dish. After 24 h of culture, medium
was changed with several doses (0, 0.1, 1, 10 or 100 WM) of troglita-
zone or pioglitazone containing culture medium and incubated for 48
h. After incubation with troglitazone or pioglitazone for 48 h, cells
were collected and centrifuged. The supernatant was aspirated and
cells were resolved with phosphate-bu¡er saline. The dead cells were
excluded by trypan blue staining. Viable cells were counted using a
hemocytometer. Next, the time-course change of cell number of
MKN45 was evaluated. After incubation with or without 100 WM
of troglitazone for 0, 12, 36 or 48 h, MKN45 cells were collected
and centrifuged. Viable cells were counted similarly.
2.9. Detection of DNA fragmentation
Cells were exposed to several doses of troglitazone, washed in cold
phosphate bu¡ered saline, and then gently homogenized in extraction
bu¡er (10 mM Tris-HCl, 10 mM EDTA and 0.2% Triton X-100 at pH
7.5) [21]. The samples were incubated for 10 min on ice and then
centrifuged at 13 000Ug for 10 min. The supernatant containing frag-
mented DNA but not intact chromatin was extracted with phenol and
chloroform precipitated with ethanol. The pellet was rinsed with 70%
ethanol, air-dried and dissolved in 1UTE (10 mM Tris-HCl and 10
mM EDTA at pH 8.0). After digestion with 0.1 mg/ml RNase A at
37‡C for 1 h, the DNA was fractionated in a 2% agarose gel and
stained with 10 Wg/ml ethidium bromide.
Fig. 1. PPARQ expression in a human gastric cancer cell line,
MKN45. A: PPARQ is expressed at the mRNA level in HT-29 and
MKN45 cells. Total RNA (1 Wg) from either HT-29 or MKN45
cells was subjected to an RT reaction with reverse transcriptase. A
1 Wl aliquot from each reaction was subjected to 40 cycles of PCR.
Ampli¢cation products were electrophoresed in a 2% agarose gel.
PPARQ expression (474 bp) is shown in lane 1 (HT-29) and lane 2
(MKN45). The L-actin control (343 bp) is shown in the right lanes
(lanes 3 and 4). B: Northern blot for PPARQ in HT-29 (lane 1) and
MKN45 (lane 2) cells. 10 Wg of each total RNA obtained from HT-
29 and MKN45 cells was electrophoresed on 2% agarose gel and
transferred to nitrocellulose membranes. Hybridization was per-
formed using a human PPARQ cDNA probe labeled with
[32P]dCTP. The L-actin control is shown in the bottom panel. C:
PPARQ protein expression in HT-29 (lane 1) and MKN45 (lane 2)
cells. 50 Wg of each protein obtained from HT-29 and MKN45 cells
was separated on SDS-PAGE and probed with an anti-PPARQ anti-
body.
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2.10. Statistical analysis
The results are expressed as mean þ S.E.M. Statistical analysis was
performed by one way analysis of variance and subsequent Fisher’s
LSD test. P6 0.05 was considered statistically signi¢cant.
3. Results
First, we examined whether PPARQ gene and protein are
expressed in MKN45 cells. Fig. 1A illustrates the representa-
tive result of PPARQ gene expression by RT-PCR. PPARQ
mRNA is expressed in both HT-29 and MKN45 cells. The
identity of the amplicon was con¢rmed by DNA sequence
analysis. As shown in Fig. 1B, PPARQ mRNA expression
was clearly detected by Northern blot analysis in MKN45
cells as in HT-29. The amount of PPARQ mRNA in
MKN45 cells was similar to that in HT-29. Fig. 1C demon-
strates a representative result of Western blot analysis. PPARQ
protein was expressed in both HT-29 and MKN45 cells. The
amount of PPARQ protein in MKN45 cells was equal to or
even higher than in HT-29 cells. In contrast, control IgG
failed to detect a product at the estimated molecular weight
(60 kDa).
We transfected MKN45 cells with an acyl-CoA oxidase
promoter-luciferase reporter plasmid containing a PPRE. Lu-
ciferase activity in the MKN45 cells treated with troglitazone
for 12 h was approximately four-fold that in untreated cells
(Fig. 2).
Next, we examined the e¡ect of PPARQ activation on cell
growth in MKN45 cells that expresses PPARQ as shown in the
above study. To activate PPARQ, we used two thiazolidine-
diones named troglitazone and pioglitazone. Fig. 3A illus-
trates the e¡ects of troglitazone on the cell number of
MKN45 cells 48 h later. Troglitazone inhibited the growth
of MKN45 cells in a dose-dependent manner. The mean num-
ber of cells (U106) with each dose of troglitazone was 3.71
(vehicle only), 4.15 (troglitazone 0.1 WM), 3.47 (1 WM), 2.63
(10 WM) or 0.67 (100 WM). Statistical signi¢cance was ob-
tained at 10 WM and higher doses of troglitazone. Fig. 3B
shows the e¡ect of another thiazolidinedione, pioglitazone,
on cell growth in MKN45 cells. As with troglitazone, co-in-
cubation of MKN45 cells with pioglitazone dose-dependently
inhibited the growth of MKN45. A signi¢cant inhibition was
seen with pioglitazone at concentrations of 1 WM and higher.
Fig. 4 shows the time-course change of MKN45 cell number
by troglitazone at a dose of 100 WM. Treatment with trogli-
tazone resulted in a signi¢cant inhibition of cell growth even
at 12 h and potent inhibition was observed throughout the
time period we tested.
Finally, we evaluated whether or not apoptosis is involved
in the inhibition of growth of MKN45 cells by troglitazone.
To assess the development of apoptosis, we checked DNA
fragmentation in MKN45 cells 48 h after application of tro-
Fig. 2. PPRE transactivation in MKN45 cells. MKN45 cells were
transfected with an acyl CoA promoter luciferase construct and
pRL-SV40. After treatment with 100 WM troglitazone for 16 h, cells
were harvested, and the dual luciferase assay was performed. Each
value is expressed as mean þ S.E.M. (n = 2).
Fig. 3. A: E¡ect of troglitazone on cell numbers of MKN45.
MKN45 cells were treated with either 0, 0.1, 1, 10 or 100 WM of
troglitazone and cell numbers were determined at 48 h. Data are ex-
pressed as mean þ S.E.M. of ¢ve experiments. ANOVA detected a
statistical signi¢cance (F(4, 20) = 19.34, P6 0.001). *P6 0.01, when
compared with vehicle only (troglitazone dose 0). B: E¡ect of pio-
glitazone on cell numbers of MKN45. MKN45 cells were treated
with either 0, 0.1, 1, 10 or 100 WM of pioglitazone and cell numbers
were determined at 48 h. Data are expressed as mean þ S.E.M. of
four or ¢ve experiments. ANOVA detected a statistical signi¢cance
(F(4, 18) = 19.50, P6 0.001). *P6 0.01, when compared with vehicle
only (pioglitazone dose 0).
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glitazone. As demonstrated in Fig. 5, DNA fragmentation was
not observed in MKN45 cells when vehicle only or troglita-
zone at concentrations of 0.1, 1 or 10 WM was co-incubated.
In contrast, clear DNA ladder formation was observed in
MKN45 cells when troglitazone had been applied at the high-
est concentration (100 WM).
4. Discussion
Increasing evidence suggests that PPARQ may be implicated
in cell di¡erentiation [22,23]. So far, PPARQ expression and
e¡ects of PPARQ agonists on cell di¡erentiation have been
investigated in colon cancer, breast cancer, prostate cancer
and liposarcoma [3,4,8^10]. However, whether or not gastric
cancer cells express PPARQ is not known. In addition, little is
known about the action of PPARQ activation on cell behavior
in gastric cancer cells. In the present study, we tried to clarify
the above two questions in a human gastric cancer cell line,
MKN45.
The present study has demonstrated that PPARQ gene and
protein expression was clearly observed in MKN45 cells.
Northern blot analysis revealed that PPARQ mRNA was ex-
pressed in the positive control HT-29, a human colon cancer
cell line. According to a previous observation [3], HT-29 ex-
presses PPARQ mRNA at a high level. When compared with
HT-29, PPARQ mRNA expression in MKN45 was detected
equally, suggesting that the gastric cancer cell line, MKN45,
expresses PPARQ mRNA at relatively high levels. Western
blot analysis also revealed equal or even higher PPARQ pro-
tein expression in MKN45 cells when compared with that in
positive control HT-29 cells. These results indicate that the
human gastric cancer cell line, MKN45, expresses PPARQ
gene and product. To determine if the PPARQ in MKN45
cells is functional as a transcriptional activator, we performed
transient transfection assays in MKN45 cells using a PPARQ-
responsive element cloned upstream of luciferase. Treatment
of the transfected cells with a PPARQ-selective agonist, trogli-
tazone, resulted in an approximately four-fold increase in lu-
ciferase activity, strongly suggesting that PPARQ expressed in
MKN45 is indeed functional as a transcriptional activator.
Since we con¢rmed that the high PPARQ expression in
MKN45 cells is functionally relevant, we next examined the
e¡ect of activation of PPARQ on cell growth in these cells. Co-
incubation of MKN45 cells with troglitazone potently inhib-
ited cell growth in a dose-related fashion. The dose-dependent
suppression of cell growth in MKN45 cells was also seen after
another thiazolidinedione, pioglitazone. These results suggest
that thiazolidinediones have a growth inhibitory action on
MKN45 cells. Since thiazolidinediones are speci¢c and high
a⁄nity agonists for PPARQ [24] and troglitazone indeed trans-
activated the transcription of a PPRE-driven promoter in the
MKN45 cells as shown in the present study, we would suggest
that PPARQ activation by thiazolidinediones may lead to
growth inhibition in gastric cancer cells.
The doses used in the present study were chosen because
they have been shown to be clinically relevant in studies of
peripheral insulin resistance [25]. The e¡ective dose range of
troglitazone to inhibit cell growth in MKN45 cells in this
study is the same as that needed to induce growth inhibition
of human colon cancer cells as shown by Sarraf et al. [3].
Sarraf et al. have demonstrated that troglitazone inhibited
colon cancer cell growth in vitro and that the growth of trans-
planted colon cancer cells was suppressed when mice were
treated with troglitazone [3]. The e¡ects of troglitazone oc-
curred at concentrations of ligand that are achieved in the
treatment of human type 2 diabetes with troglitazone [25].
This evidence may suggest that troglitazone at doses used
clinically may induce inhibition of growth of colon cancer
cells. The same dose range of troglitazone that induced inhibi-
tion of cell growth in colon cancer and gastric cancer cells in
vitro suggests that anti-tumor action of troglitazone for gas-
tric cancer might be given at clinically relevant doses of tro-
glitazone.
The mechanism by which troglitazone induces growth in-
hibition in MKN45 cells remained to be clari¢ed. To address
this problem, we examined the possibility that apoptosis is
involved in growth suppression. Neither vehicle only nor
low doses of troglitazone induced apoptosis in MKN45 cells.
However, troglitazone at the highest concentrations (100 WM)
tested in this study induced an apparent DNA fragmentation
Fig. 4. Time-course change of cell number by troglitazone. MKN45
cells were treated with either vehicle only or 100 WM of troglitazone
and cell numbers were determined at 0, 12, 36 or 48 h. Data are ex-
pressed as mean þ S.E.M. of six experiments. *P6 0.01, when com-
pared with vehicle only (DMSO).
Fig. 5. DNA fragmentation induced by troglitazone in MKN45
cells. MKN45 cells were treated with troglitazone in a dose of 0,
0.1, 1.0, 10 or 100 WM, and 48 h later DNA solution obtained from
MKN45 cells was separated on a 2% agarose gel and then stained
with 10 Wg/ml ethidium bromide. DNA samples applied in this ex-
periment were obtained according to a previous report [21]. In this
procedure, the samples contain fragmented DNA but not intact
DNA. Every two results in each dose of troglitazone are shown.
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in MKN45 cells, suggesting an apoptotic change. Chinetti et
al. [26] have recently shown that PPARQ activation induces
apoptosis in human monocyte-derived macrophage. The evi-
dence obtained from benign cells might support our specula-
tion that PPARQ activation by troglitazone could induce
apoptosis in malignant cells. The present evidence that the
dose (100 WM) of troglitazone potently inhibited cell growth
and induced apoptosis revealed that apoptosis might be in-
volved in the mechanisms by which troglitazone at a dose of
100 WM prevented cell growth in gastric cancer cells. How-
ever, the dose-response e¡ect of troglitazone on the induction
of apoptosis was much less potent than that on the inhibition
of cell growth. These results may suggest that apoptosis is not
a major mechanism by which troglitazone induced the inhibi-
tion of cell growth.
A couple of reports show that PPARQ is closely associated
with cell cycle to alter cell growth. Altiok et al. [27] reported
that the reduction in cell growth is closely associated with a
loss of E2F/DP DNA binding through modulation of phos-
phorylation by PP2A phosphatase in ¢broblasts. Brockman et
al. [4] demonstrated that activation of PPARQ resulted in G1
cell cycle arrest in colon cancer cells. Thus, cell cycle with-
drawal together with induction of apoptosis might be impli-
cated in the troglitazone-induced growth inhibition of gastric
cancer cells. Further studies are needed in this matter.
Based on data about the relative time trends of the age-
adjusted mortality rate for gastric cancer in Japan in 1955^
1993, gastric cancer mortality has shown a declining trend
since around 1960 and the mortality rate in 1993 is about
50% or less than in 1955. The reason for the marked change
over time in the mortality rate of gastric cancer in Japan is
not clear. With regard to this point, Tominaga and Kuroishi
[28] examined the relationship between diet/nutrition and in-
cidence of gastric cancer and showed that increased fat intake
may be inversely associated with mortality of gastric cancer.
This result may indicate that increased fat intake may be one
of the factors to decrease the incidence of gastric cancer in
Japan. It has been shown that fat activates PPARQ. For ex-
ample, PPARQ modulates gene expression in response to fatty
acids and lipid-derived metabolites [1,2]. We may therefore be
allowed to speculate that PPARQ activation by increased in-
take of fatty food might have a suppressive action on the
development of gastric cancers in Japan. In other words,
PPARQ activation may provide a molecular link between a
high-fat diet and decreased risk of gastric cancer.
In summary, the present study shows that PPARQ is ex-
pressed in human gastric cancer cells and that PPARQ activa-
tion inhibits cell growth and induces apoptosis.
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